Sage Journals: Discover world-class research

Abstract

Spinal muscular atrophy (SMA) is a neuromuscular disease caused by mutations in survival motor neuron 1 (SMN1). Previously, we showed that central nervous system (CNS) delivery of an adeno-associated viral (AAV) vector encoding SMN1 produced significant improvements in survival in a mouse model of SMA. Here, we performed a dose–response study in SMA mice to determine the levels of SMN in the spinal cord necessary for efficacy, and measured the efficiency of motor neuron transduction in the spinal cord after intrathecal delivery in pigs and nonhuman primates (NHPs). CNS injections of 5e10, 1e10, and 1e9 genome copies (gc) of self-complementary AAV9 (scAAV9)–hSMN1 into SMA mice extended their survival from 17 to 153, 70, and 18 days, respectively. Spinal cords treated with 5e10, 1e10, and 1e9 gc showed that 70–170%, 30–100%, and 10–20% of wild-type levels of SMN were attained, respectively. Furthermore, detectable SMN expression in a minimum of 30% motor neurons correlated with efficacy. A comprehensive analysis showed that intrathecal delivery of 2.5e13 gc of scAAV9-GFP transduced 25–75% of the spinal cord motor neurons in NHPs. Thus, the extent of gene expression in motor neurons necessary to confer efficacy in SMA mice could be obtained in large-animal models, justifying the continual development of gene therapy for SMA.

Get full access to this article

View all access options for this article.

References

Amado

, et al. (2010). Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci. Transl. Med., 2, e21ra16.

Avila

A.M.

, et al. (2007). Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest., 117, 659–671.

Bankiewicz

K.S.

, et al. (2006). Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol. Ther., 14, 564–570.

Bebee

T.W.

, et al. (2012). Mouse models of SMA: tools for disease characterization and therapeutic development. Hum. Genet., 131, 1277–1293.

Bevan

A.K.

, et al. (2011). Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther., 19, 1971–1980.

Bowerman

, et al. (2012). A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology. Neuromuscul. Disord., 22, 263–276.

Burghes

A.H.

, and Beattie

C.E.

(2009). Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nat. Rev. Neurosci., 10, 597–609.

Butchbach

M.E.

, et al. (2010). Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum. Mol. Genet., 19, 454–467.

Chen

T.H.

, et al. (2010). Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. Neurology, 75, 2190–2197.

10.

Dominguez

, et al. (2011). Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet., 20, 681–693.

11.

Duque

, et al. (2009). Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther., 17, 1187–1196.

12.

Farooq

, et al. (2011). Prolactin increases SMN expression and survival in a mouse model of severe spinal muscular atrophy via the STAT5 pathway. J. Clin. Invest., 121, 3042–3050.

13.

Federici

, et al. (2012). Robust spinal motor neuron transduction following intrathecal delivery of AAV9 pigs. Gene Ther., 19, 852–859.

14.

Foust

K.D.

, et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotech., 28, 271–274.

15.

Garbes

, et al. (2009). LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum. Mol. Genet., 18, 3645–3658.

16.

Gavrilina

T.O.

, et al. (2008). Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. Hum. Mol. Genet., 17, 1063–1075.

17.

Gray

S.J.

, et al. (2011). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther., 19, 1058–1069.

18.

Gray

S.J.

, et al. (2013). Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther., 20, 450–459.

19.

Hamilton

, and Gillingwater

T.H.

(2013). Spinal muscular atrophy: going beyond the motor neuron. Trends Mol. Med., 19, 40–50.

20.

Hua

, et al. (2008). Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet., 82, 834–848.

21.

Hua

, et al. (2010). Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev., 24, 1634–1644.

22.

Hua

, et al. (2011). Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature, 478, 123–126.

23.

Kolb

S.J.

, and Kissel

J.T.

(2011). Spinal muscular atrophy: a timely review. Arch. Neurol., 68, 979–984.

24.

Kole

, et al. (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Dis., 11, 125–140.

25.

T.T.

, et al. (2005). SMNΔ7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet., 14, 845–857.

26.

Lefebvre

, et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell, 80, 155–165.

27.

Lorson

C.L.

, et al. (1999). A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA, 96, 6307–6311.

28.

Lorson

M.A.

, et al. (2011). Disruption of the survival motor neuron (SMN) gene in pigs using ssDNA. Transgenic Res., 20, 1293–1304.

29.

Lewelt

, et al. (2012). New therapeutic approaches to spinal muscular atrophy. Curr. Neurol. Neurosci. Rep., 12, 42–53.

30.

Markowitz

J.A.

, et al. (2012). Spinal muscular atrophy: a clinical and research update. Ped. Neurol., 46, 1–12.

31.

Mattis

V.B.

, et al. (2009). Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum. Mol. Genet., 18, 3906–3913.

32.

Mercuri

, et al. (2007). Randomized, double blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology, 68, 51–55.

33.

Monani

U.R.

, et al. (1999). A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet., 8, 1177–1183.

34.

Nathwani

A.C.

, et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365, 2357–2365.

35.

Passini

M.A.

, and Cheng

S.H.

(2011). Prospects for the gene therapy of spinal muscular atrophy. Trends Mol. Med., 17, 259–265.

36.

Passini

M.A.

, et al. (2010). CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest., 120, 1253–1264.

37.

Passini

M.A.

, et al. (2011). Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med., 3, 72ra18.

38.

Rudnik-Schöneborn

, et al. (2008). Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J. Med. Genet., 45, 635–638.

39.

Samaranch

, et al. (2012). Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther., 23, 382–389.

40.

Singh

N.K.

, et al. (2006). Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol., 26, 1333–1346.

41.

Sumner

C.J.

, et al. (2003). Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol., 54, 647–654.

42.

Valori

C.F.

, et al. (2010). Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med., 2, 35ra42.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.10 MB

Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9–Survival Motor Neuron 1 for Spinal Muscular Atrophy

Abstract

Get full access to this article

References

Supplementary Material